SingleMetabolic / GLP-1

Mazdutide 5mg

Dual GLP-1 and glucagon receptor agonist evaluated in clinical models for robust metabolic regulation and body weight reduction.

Mechanism

Acts as a dual agonist co-activating both GLP-1 and glucagon receptors to simultaneously suppress appetite, delay gastric emptying, and elevate hepatic energy expenditure.

Dosing

Standard reference protocols initiate exploration at 2.5 mg administered subcutaneously once weekly for the initial 4-week titration phase.

Reconstitution

Reconstituting a 5 mg vial with 3.0 mL of bacteriostatic water yields an approximate working concentration of 1.67 mg/mL (1,667 mcg/mL).

Storage

Store dry lyophilized vials frozen at -20 °C; once reconstituted, refrigerate at 2–8 °C, protect from light, and do not freeze.

Mix & measure Mazdutide 5mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Mazdutide 5mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration1.67mg/mL

Draw volume1.50mL

On the syringe150.0units

Total doses in vial: 2.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–4	2.5 mg once weekly	150 units (1.50 mL)
Weeks 5–8+	5.0 mg once weekly	300 units (3.00 mL)

Reconstitution Steps

1
Draw 3.0 mL of bacteriostatic water into a sterile reconstitution syringe.
2
Insert the needle into the 5 mg Mazdutide vial and allow the liquid to flow slowly down the inner glass wall to prevent excessive foaming.
3
Gently roll or swirl the vial until the lyophilized cake is fully dissolved; do not shake aggressively.
4
Record the date and resulting concentration (~1.67 mg/mL) on the vial label.
5
Store the reconstituted solution protected from light in a laboratory refrigerator at 2–8 °C.

Supplies Needed

Peptide Vial

Mazdutide 5 mg lyophilized powder vial for laboratory reconstitution.

Insulin Syringes (U-100)

Calibrated U-100 sterile syringes for precise measurement and subcutaneous administration.

Bacteriostatic Water

Sterile diluent containing 0.9% benzyl alcohol used to reconstitute the peptide cake.

Alcohol Swabs

70% isopropyl alcohol prep pads for disinfecting vial septums and injection sites.

Why researchers study it

Weight management and adiposity reduction

Appetite suppression and satiety signaling

Glycemic regulation and HbA1c moderation in type 2 diabetes models

Glucagon-driven hepatic fat metabolism and energy expenditure

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Mazdutide (also referenced in literature as IBI362 or LY3305677) is an investigational synthetic peptide designed to simultaneously stimulate both glucagon-like peptide-1 (GLP-1) and glucagon receptors. By co-activating these complementary pathways, researchers aim to harness both incretin-driven appetite suppression and glucagon-mediated thermogenic energy expenditure. In controlled multi-week clinical trials, the compound has shown notable efficacy in reducing adiposity and improving glycemic indices relative to baseline. Preclinical and clinical evaluations highlight a favorable pharmacokinetic profile characterized by an extended half-life, enabling once-weekly subcutaneous evaluation schedules. Dose-titration paradigms are universally implemented in literature to mitigate transient gastrointestinal reactivity, systematically escalating subjects from an initial exposure dose to target maintenance levels over multiple weeks. While mazdutide obtained regulatory clearance via China's NMPA for weight management and glycemic regulation in type 2 diabetes, it remains an unapproved investigational substance under regulatory bodies such as the US FDA and EMA. All referenced handling parameters, concentrations, and protocols are documented strictly for academic, laboratory, and scientific benchmarking.

References

1.EClinicalMedicine (PubMed), 2021 — Phase 1b trial: safety and efficacy of mazdutide 9–10 mg in Chinese adults with overweight or obesity
2.Nature Communications, 2022 — Phase 2 randomized controlled trial of mazdutide in Chinese adults with overweight or obesity
3.New England Journal of Medicine, 2024 — Phase 3 trial: once-weekly mazdutide in Chinese adults with obesity or overweight (48-week results)
4.Diabetes Care (PubMed), 2023 — Phase 2 trial: efficacy and safety of mazdutide in Chinese patients with type 2 diabetes
5.Frontiers in Endocrinology, 2024 — Systematic review and meta-analysis of mazdutide for weight loss in diabetic and non-diabetic patients
6.International Journal of Obesity (Nature), 2023 — Review of the pipeline for future obesity medications, including GLP-1 / glucagon dual agonists such as mazdutide